Latest news with #precisionmedicine
Yahoo
6 days ago
- Business
- Yahoo
Why Tempus AI Stock Soared 15% Today
Tempus AI was targeted by a short seller last week. Since then, the company has made several announcements that have helped quell doubts introduced by the short report. TD Cowen maintained its buy rating today. 10 stocks we like better than Tempus Ai › Shares of Tempus AI (NASDAQ: TEM) soared on Monday. The company's stock jumped 15% as of market close. The spike comes as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC) jumped 0.4% and 0.6%, respectively. Tempus, a "precision medicine" company that leverages artificial intelligence (AI) to better treat patients, was the target of a short report last week alleging, among other things, that Tempus is overstating its use of AI. On Friday and Saturday, the company made announcements regarding two AI-driven programs. Whether the timing was deliberate or not, the announcements appeared to help quell doubts introduced by the short seller allegations. Tempus One, the company's AI platform that is intended to help physicians make better decisions, got a key update. The company announced Saturday that the platform will now have direct access to electronic health records (EHR) systems. As the company describes it, the expanded access to data allows the platform to "capture real-time clinical, molecular and imaging data from millions of patients and makes that data easily digestible and useful for clinicians and care teams." On Friday, the company announced an initiative it calls Fuses. The company says it will use its vast amount of clinical data to create "an AI-enabled diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality." Today, investors were also pleased to see that TD Cowen is maintaining its buy rating, unconvinced by the short seller's allegations. Despite this, and the company's recent announcements, I believe that Tempus' stock is currently overvalued even if the short seller's allegations don't hold up. Before you buy stock in Tempus Ai, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Tempus Ai wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Tempus AI Stock Soared 15% Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
02-06-2025
- Business
- Associated Press
Precede Biosciences Presents ASCO 2025 Data Highlighting the Ability of its Liquid Biopsy Platform to Reveal the Biology Underlying Response and Resistance to ADCs and Radiopharmaceuticals
BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, today shared the company's scientific presentations from the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting taking place from May 30 to June 3, 2025, in Chicago, Illinois. 'In metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617, comprehensive epigenomic profiling of plasma not only captured PSMA expression, but also revealed that elevated Wnt signaling and reduced immune activity at baseline were associated with inferior outcomes,' said Jacob E. Berchuck, MD, Assistant Professor, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University. 'These findings highlight the potential of this approach to provide novel insights into molecular correlates of therapeutic response and resistance.' 'Plasma-based comprehensive epigenomic profiling enables high-resolution characterization of tumor-intrinsic transcriptional programs and resistance pathways. In this study, we applied this approach to HR+/HER2- metastatic breast cancer patients treated with sacituzumab govitecan with or without pembrolizumab, revealing distinct immune and proliferative pathways associated with therapeutic response,' said Ana C. Garrido-Castro, MD, Medical Oncologist, Dana-Farber Cancer Institute, Assistant Professor of Medicine at Harvard Medical School. 'These findings could guide future trial designs by informing selection of combination versus monotherapy strategies based on underlying tumor biology.' 'Our ASCO presentations underscore the potential of the Precede Bio platform to decode the transcriptional biology underlying response and resistance to two leading next-generation precision therapies,' said Carl Barrett, Chief Scientific Officer of Precede Bio. 'What sets our platform apart is its ability to deliver this level of biological insight through a minimally invasive and highly interpretable approach. We are excited to continue collaborating with drug developers and academic leaders to help guide the development and application of emerging precision medicines—including drug-, radio-, and immune-conjugates.' Data presented at the ASCO Annual Meeting can be found in the presentations section of the company website and below: Robust characterization of response & resistance to 177Lu-PSMA-617 in mCRPC by plasma-based epigenomic profiling Cell-free circulating chromatin profiles enable epigenomic characterization of mechanisms of response and resistance to sacituzumab govitecan in breast cancer About Precede Biosciences Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be learned from a simple blood draw. By understanding the fundamental biology behind disease at any given moment, researchers and clinicians can better target medicines to the right patients in both drug development and clinical practice. Precede Bio seeks to improve success rates in drug development and to be a part of building a future where every patient can receive a rapid, minimally invasive diagnosis and therapy that is precise to the biology of their disease. Precede Bio's platform is available to drug developers and academic researchers. To learn more, visit or follow us on LinkedIn. Media Contact: Donelle M. Gregory [email protected]
Associated Press
01-06-2025
- Business
- Associated Press
Introducing Tempus One in the EHR with Integrated Guidelines
CHICAGO--(BUSINESS WIRE)--Jun 1, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of Tempus One—its generative AI clinical assistant—with direct integration into electronic health record (EHR) systems. By integrating AI at every point of the clinical care process, the expanded capabilities of Tempus One offer physicians in oncology and beyond more support in treatment decisions. Tempus One is uniquely positioned to offer these new features given the company's depth and scale of EHR integrations with providers across the U.S. Tempus has developed an integrated architecture that captures real-time clinical, molecular and imaging data from millions of patients and makes that data easily digestible and useful for clinicians and care teams. Through Tempus One, physicians can gain AI-enabled insights that transform how they interact with patient data, streamlining complex treatment decisions and reducing time spent on administrative tasks. New capabilities in the latest iteration of Tempus One: 'As healthcare faces rising costs and growing complexity, no group bears the burden more heavily than physicians and care teams,' said Ryan Fukushima, Chief Operating Officer at Tempus. 'This evolution of Tempus One represents a meaningful shift from a world where clinicians spend countless hours searching for answers and documenting care, to one where AI rapidly connects the dots across fragmented systems to deliver actionable insights in real time.' To learn more about Tempus One, view a video here and visit the website here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of Tempus One and its capabilities for customers. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. View source version on CONTACT: Erin Carron [email protected] KEYWORD: ILLINOIS UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: APPS/APPLICATIONS TECHNOLOGY HEALTH TECHNOLOGY SOFTWARE NETWORKS HEALTH GENERAL HEALTH ARTIFICIAL INTELLIGENCE ONCOLOGY SOURCE: Tempus AI, Inc. Copyright Business Wire 2025. PUB: 06/01/2025 08:30 AM/DISC: 06/01/2025 08:31 AM
Yahoo
01-06-2025
- Business
- Yahoo
Introducing Tempus One in the EHR with Integrated Guidelines
The AI-enabled clinical assistant is available to query patient data across the EHR as well as build custom agents to maximize workflow CHICAGO, June 01, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of Tempus One—its generative AI clinical assistant—with direct integration into electronic health record (EHR) systems. By integrating AI at every point of the clinical care process, the expanded capabilities of Tempus One offer physicians in oncology and beyond more support in treatment decisions. Tempus One is uniquely positioned to offer these new features given the company's depth and scale of EHR integrations with providers across the U.S. Tempus has developed an integrated architecture that captures real-time clinical, molecular and imaging data from millions of patients and makes that data easily digestible and useful for clinicians and care teams. Through Tempus One, physicians can gain AI-enabled insights that transform how they interact with patient data, streamlining complex treatment decisions and reducing time spent on administrative tasks. New capabilities in the latest iteration of Tempus One: Integration of ASCO Guidelines: Tempus One is integrating ASCO's clinical practice guidelines into the platform to equip physicians with the latest guidelines and information to guide personalized patient care. Oncologists are now able to easily access ASCO's guidelines, which provide evidence-based, treatment and care recommendations. Clinical Workflow Assistance: Tempus One has a suite of new features, designed to help physicians at every step with tailored insights and reduce the burden of administrative tasks. Pre-Appointment Preparation: Tempus One summarizes patient history, treatment journey, and recent biomarker status, ensuring physicians are well-prepared for appointments. Real-Time Support During Appointments: Tempus One can transcribe conversations, take intelligent notes, and highlight key information, allowing physicians to focus on patient care. Post-Appointment Assistance: Tempus One supports documentation tasks, treatment planning based on updated guidelines and research, prepares prior authorizations, and facilitates clinical trial matching. Agent Builder: Over the past several months, Tempus has used its Agent Builder GenAI tool internally to develop and deploy more than 1,000 AI agents. Now, Tempus is extending access to this toolset to a select group of partner providers, collaborating with them to create and test custom GenAI solutions tailored to their unique needs and preferences. The agents are designed to create efficiencies and streamline workflows, such as generating custom patient overviews to accelerate pre-charting or generating notes from conversations with patients to be added into their EHR records. These custom agents can be developed in collaboration with dedicated Tempus team members. By referencing institutions' standard operating procedures and data repositories, these agents can be seamlessly integrated into existing workflows through One. "As healthcare faces rising costs and growing complexity, no group bears the burden more heavily than physicians and care teams," said Ryan Fukushima, Chief Operating Officer at Tempus. "This evolution of Tempus One represents a meaningful shift from a world where clinicians spend countless hours searching for answers and documenting care, to one where AI rapidly connects the dots across fragmented systems to deliver actionable insights in real time." To learn more about Tempus One, view a video here and visit the website here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of Tempus One and its capabilities for customers. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ("SEC") on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. View source version on Contacts Erin Carronmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31-05-2025
- Business
- Yahoo
Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
The initiative will apply its massive, multimodal dataset to build models that aim to improve diagnostic, prognostic, and predictive modeling CHICAGO, May 31, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of its Fuses program. This initiative will harness Tempus' proprietary dataset to generate valuable insights for both patient care and research, combining the power of its data and machine learning capabilities to develop an AI enabled-diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality. Over the past decade, Tempus has built a multimodal data library of over 40 million research records, including more than 1.5 million records with matched clinical data linked with genomic information, 2 million records with imaging data, and approximately 300,000 records with genomic and whole transcriptomic data. The scale and size of this data library will allow the company to uncover groundbreaking discoveries that were previously out of reach. Fuses will accelerate Tempus' comprehensive testing portfolio, expanding its suite of AI-enabled diagnostics. Insights from Fuses will be developed into clinically validated algorithmic diagnostics that may enable highly personalized care, such as identifying patients unlikely to respond to approved therapies or those at risk of severe treatment-related events. Tempus has already begun this work with last year's launch of its Immune Profile Score (IPS) a multimodal biomarker that can be used as a prognostic indicator for adult patients with metastatic pan-solid tumors eligible for immune checkpoint inhibitor (ICI)-based therapy. "We have spent the last ten years building, scaling, and curating one of the most comprehensive datasets in our industry, and now we are well positioned to develop the world's largest diagnostic model, designed to answer critical, unsolved questions and make our diagnostics smarter and more personalized," said Eric Lefkofsky, Founder and CEO of Tempus. "We are on the brink of delivering tangible, transformative change in matching the right therapies to the right patients - making personalized care a reality for millions." The foundational model behind Fuses is learning generalizable rules determining prognosis and drug benefit in real-world practice. With the goal of furthering researchers' understanding of why certain clinical trials fail, identify new indications for investigational drugs, optimize trial design, and uncover combination therapies to broaden patient benefit. By revealing biomarker rules, the model may also surface mechanisms of drug response and resistance to inspire a new generation of companion diagnostics and therapeutic research. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of Fuses and its insights in oncology clinical care and therapeutic research and discovery, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ("SEC") on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. View source version on Contacts Erin Carronmedia@
